Payment overview · 2025
General Payments
$495.58
31 reported records · 11 companies
Healthcare provider profile · identity verified
Bridgett A Cooper, MD
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1518944792
Verified facts
What the public records show
CMS Open Payments records show Bridgett A Cooper, MD received $495.58 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $144.03 | 29.1% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.78 | 17.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.19 | 10.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.98 | 7.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.16 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.13 | 7.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.09 | 5.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.57 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.27 | 3.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.05 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.33 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.58 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.81 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.69 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.26 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.26 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.26 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 13 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 216 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 44 |
| Lisinopril | Lisinopril | 182 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 41 |
| Meloxicam | Meloxicam | 121 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 23 |
| Omeprazole | Omeprazole | 92 | 26 |
| Losartan Potassium | Losartan Potassium | 86 | 25 |
| Alendronate Sodium | Alendronate Sodium | 83 | 23 |
| Alprazolam | Alprazolam | 75 | 16 |
| Simvastatin | Simvastatin | 74 | 20 |
| Metformin Hcl Er | Metformin Hcl | 72 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Furosemide | Furosemide | 65 | 12 |
| Gabapentin | Gabapentin | 65 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 17 |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Metformin Hcl | Metformin Hcl | 57 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Estradiol | Estradiol | 54 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 15 |
| Ezetimibe | Ezetimibe | 51 | 15 |
| Potassium Chloride | Potassium Chloride | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 17 |
| Celecoxib | Celecoxib | 48 | 11 |
| Famotidine | Famotidine | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 16 |
| Allopurinol | Allopurinol | 40 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Eliquis | Apixaban | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 22 |
| Baclofen | Baclofen | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.58 · 31 records | ABBVIE INC. | ABRYSVO, COMIRNATY, CREON, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, UBRELVY, VOQUEZNA, WATCHMAN FLX, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error